Cart
sales@molnova.com
CMPD-1
CAS No. 41179-33-3
CMPD-1( CMPD 1 | CMPD1 )
Catalog No. M14412 CAS No. 41179-33-3
A potent, selective, non-ATP-competitive inhibitor of p38α-mediated MK2a phosphorylation with apparent Ki of 330 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 110 | In Stock |
|
| 5MG | 101 | In Stock |
|
| 10MG | 155 | In Stock |
|
| 25MG | 281 | In Stock |
|
| 50MG | 433 | In Stock |
|
| 100MG | 671 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 1572 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCMPD-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, selective, non-ATP-competitive inhibitor of p38α-mediated MK2a phosphorylation with apparent Ki of 330 nM.
-
DescriptionA potent, selective, non-ATP-competitive inhibitor of p38α-mediated MK2a phosphorylation with apparent Ki of 330 nM; dose not prevents p38α-mediated phosphorylation of MBP and ATF-2; induces a significant G2/M arrest, also inhibits tubulin polymerization in glioblastoma cells.
-
In VitroCMPD1 does not inhibit p38 MAPK-mediated phosphorylation of other two substrates, MBP and ATF2.CMPD1 induced mitotic arrest and apoptosis in U87 cells.CMPD1 inhibits tubulin polymerisation in glioblastoma cells.
-
In Vivo——
-
SynonymsCMPD 1 | CMPD1
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
Recptorp38 MAPK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number41179-33-3
-
Formula Weight349.4
-
Molecular FormulaC22H20FNO2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (286.20 mM)
-
SMILESO=C(NC1=CC=C(O)C=C1)CCCC2=CC=C(C3=CC=CC=C3F)C=C2
-
Chemical Name4-(2'-fluoro-[1,1'-biphenyl]-4-yl)-N-(4-hydroxyphenyl)butanamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Davidson W, et al. Biochemistry. 2004 Sep 21;43(37):11658-71.
2. Gurgis F, et al. Cell Death Discov. 2015 Sep 7;1:15028.
molnova catalog
related products
-
p38α inhibitor 4
p38α inhibitor 4 is a selective MAPK p38α inhibitor, which is used to study diabetes, pain and chronic inflammation.
-
SC-806
A potent, orally active p38 MAPK inhibitor with IC50 of 50 nM.
-
Zunsemetinib
Zunsemetinib (ATI-450) is an orally active and selective inhibitor of the p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway.
